Country: Afrika Selatan
Bahasa: Inggeris
Sumber: South African Health Products Regulatory Authority (SAHPRA)
Lennon
MOXYPEN®-250 CAPSULES MOXYPEN®-500 CAPSULES MOXYPEN® 125 mg/5 mLPOWDER FOR SYRUP MOXYPEN® 250 mg/5 mLPOWDER FOR SYRUP SCHEDULING STATUS: S4 PROPRIETARY NAME: (and dosage form) MOXYPEN ® -250 CAPSULES MOXYPEN ® -500 CAPSULES MOXYPEN ® 125 mg/5 mLPOWDER FOR SYRUP MOXYPEN ® 250 mg/5 mLPOWDER FOR SYRUP COMPOSITION: Capsules containing Amoxycillin trihydrate equivalent to Amoxycillin 250 mg and 500 mg, and powder for preparing fruit-flavoured syrups. When dispensed as directed, each 5 mL of the syrup contains Amoxycillin trihydrate equivalent to 125 mg or 250 mg Amoxycillin. The powder contains 0,1% m/v Sodium benzoate B.P. as a preservative. PHARMACOLOGICAL CLASSIFICATION: A 20.1.2 Penicillins. PHARMACOLOGICAL ACTION: Amoxycillin is a penicillinase-susceptible semisynthetic penicillin. It is bactericidal in vitro against a broad spectrum of gram-positive and gram-negative pathogens. Being acid stable Amoxycillin is well absorbed when given orally. Peak plasma concentrations are reached at 2 hours and average about 4 micrograms/mL when 250 mg is administered. The in vitro antibacterial spectrum of Moxypen is as follows (in vitro sensitivity does not necessarily imply in vivo efficacy): Moxypen is particularly active in vitro against the following organisms: Gram-positive organisms: Streptococcus pneumoniae*, Streptococcus faecalis* (enterococci), Streptococcus agalactiae (group B), penicillin- sensitive Neisseria gonorrhoeae, Listeria monocytogenes: Moxypen is also active in vitro against the following organisms: Gram-positive organisms: Staphylococcus aureus* (penicillin sensitive), Streptococcus pyogenes, Streptococcus viridans*, Streptococcus bovis, Neisseria meningitidis (except the carrier state), Bacillus anthracis*, Corynebacterium species*, Clostridium species*:Moxypen also has in vitro activity aga Baca dokumen lengkap